News Brilique boosted by NICE’s long-term prevention recommendati... Recommendation will add to growth trajectory
News AZ's key drug Brilique fails in stroke trial Disappointment for AstraZeneca and key growth driver
Oncology ASCO 2026: Three ADC approvals in five days, with Ken Keller... At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
